Conjugated estrogens/medroxyprogesterone acetate

Conjugated estrogens/medroxyprogesterone acetate (CEs/MPA), sold under the brand names Prempro and Premphase, is a combination product of conjugated estrogens (Premarin), an estrogen, and medroxyprogesterone acetate (Provera), a progestogen, which is used in menopausal hormone therapy for the treatment of menopausal symptoms.[1]

Health risks in the CEEs/MPA substudy of the Women's Health Initiative
EventRelative Risk CEEs/MPA vs. placebo at 5.2 years (95% CI[note 1])Placebo
(n = 8102)		CEEs/MPA
(n = 8506)
Absolute Risk per 10,000 Women-Years
Coronary heart disease events
( non-fatal myocardial infarction, death)		1.29 (1.02–1.63)
1.32 (1.02–1.72)
1.18 (0.70–1.97)		30
23
6		37
30
7
Invasive breast cancer[lower-alpha 1]1.26 (1.00–1.59)3038
Stroke1.41 (1.07–1.85)2129
Pulmonary embolism2.13 (1.39–3.25)816
Colorectal cancer0.63 (0.43–0.92)1610
Endometrial cancer0.83 (0.47–1.47)65
Hip fracture0.66 (0.45–0.98)1510
Death due to causes other than above0.92 (0.74–1.14)4037
Global Index[lower-alpha 2]1.15 (1.03–1.28)151170
Deep vein thrombosis[lower-alpha 3]2.07 (1.49–2.87)1326
Vertebral fractures[lower-alpha 3]0.66 (0.44–0.98)159
Other osteoporotic fractures[lower-alpha 3]0.77 (0.69–0.86)170131
Sources: See template.
Conjugated estrogens /
medroxyprogesterone acetate
Combination of
Conjugated estrogensEstrogen
Medroxyprogesterone acetateProgestogen
Clinical data
Trade namesPrempro, Premphase
Other namesCEs/MPA; CEEs/MPA
Routes of
administration		By mouth
Drug classEstrogen; Progestogen
Legal status
Legal status

See also

Notes and references
  1. MaryAnne Hochadel; Jerry Avorn (1 January 2007). The AARP Guide to Pills: Essential Information on More Than 1,200 Prescription and Nonprescription Medications, Including Generics. Sterling Publishing Company Incorporated. pp. 235–. ISBN 978-1-4027-4446-4.
  1. Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.
  2. A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.
  3. Not included in Global Index.
  1. Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.